A correlative study of polymorphisms of CYP2C19 and MDR1 C3435T with the pharmacokinetic profiles of lansoprazole and its main metabolites following single oral administration in healthy adult Chinese subjects
详细信息 查看全文
- 作者：Chang-Yin Li (1)
Jun Zhang (1)
Ji-Hong Chu (1)
Mei-Juan Xu (1)
Wen-Zheng Ju (1)
Fang Liu (1)
Jian-Dong Zou (1) - 关键词：Lansoprazole ; Metabolites ; MDR1 C3435T ; CYP2C19 ; Genetic polymorphism ; Pharmacokinetics
- 刊名：European Journal of Drug Metabolism and Pharmacokinetics
- 出版年：2014
- 出版时间：June 2014
- 年：2014
- 卷：39
- 期：2
- 页码：121-128
- 全文大小：
- 参考文献：1. Barradell LB, Faulds D, McTavish D (1992) Lansoprazole. A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders. Drugs 44(2):225-50 CrossRef
2. Cascorbi I, Gerloff T, Johne A, Meisel C, Hoffmeyer S, Schwab M, Schaeffeler E, Eichelbaum M, Brinkmann U, Roots I et al (2001) Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 69(3):169-74. doi:10.1067/mcp.2001.114164 CrossRef
3. De Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA et al (1994a) Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 46(4):594-98
4. de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA et al (1994b) The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 269(22):15419-5422
5. Delhotal-Landes B, Cournot A, Vermerie N, Dellatolas F, Benoit M, Flouvat B et al (1991) The effect of food and antacids on lansoprazole absorption and disposition. Eur J Drug Metab Pharmacokinet Spec No 3:315-20
6. Delhotal-Landes B, Flouvat B, Duchier J, Molinie P, Dellatolas F, Lemaire M et al (1993) Pharmacokinetics of lansoprazole in patients with renal or liver disease of varying severity. Eur J Clin Pharmacol 45(4):367-71 CrossRef
7. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, Brinkmann U et al (2000) Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 97(7):3473-478. doi:10.1073/pnas.050585397 CrossRef
8. Hu YR, Qiao HL, Kan QC (2004) Pharmacokinetics of lansoprazole in Chinese healthy subjects in relation to CYP2C19 genotypes. Acta Pharmacol Sin 25(8):986-90
9. Hussein Z, Granneman GR, Mukherjee D, Samara E, Hogan DL, Koss MA, Isenberg JI et al (1993) Age-related differences in the pharmacokinetics and pharmacodynamics of lansoprazole. Br J Clin Pharmacol 36(5):391-98 CrossRef
10. Katsuki H, Nakamura C, Arimori K, Fujiyama S, Nakano M et al (1997) Genetic polymorphism of CYP2C19 and lansoprazole pharmacokinetics in Japanese subjects. Eur J Clin Pharmacol 52(5):391-96 CrossRef
11. Kodaira C, Sugimoto M, Nishino M, Yamade M, Shirai N, Uchida S, Ikuma M, Yamada S, Watanabe H, Hishida A, Furuta T et al (2009) Effect of MDR1 C3435T polymorphism on lansoprazole in healthy Japanese subjects. Eur J Clin Pharmacol 65(6):593-00. doi:10.1007/s00228-009-0625-8 CrossRef
12. Miura M, Inoue K, Satoh S, Itoh Y, Kagaya H, Tada H, Tanaka Y, Habuchi T, Suzuki T et al (2007) Influence of cytochrome P450 (CYP) 3A5 polymorphisms on the pharmacokinetics of lansoprazole enantiomers in CYP2C19 extensive metaboliser renal transplant recipients. Clin Drug Investig 27(4):251-58 CrossRef
13. Pauli-Magnus C, Rekersbrink S, Klotz U, Fromm MF et al (2001) Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein. Naunyn Schmiedeberg’s Arch Pharmacol 364(6):551-57 CrossRef
14. Pichard L, Curi-Pedrosa R, Bonfils C, Jacqz-Aigrain E, Domergue J, Joyeux H, Cosme J, Guengerich FP, Maurel P et al (1995) Oxidative metabolism of lansoprazole by human liver cytochromes P450. Mol Pharmacol 47(2):410-18
15. Siegmund W, Ludwig K, Giessmann T, Dazert P, Schroeder E, Sperker B, Warzok R, Kroemer HK, Cascorbi I et al (2002) The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol. Clin Pharmacol Ther 72(5):572-83. doi:10.1067/mcp.2002.127739 CrossRef
16. Song M, Gao X, Hang T, Wen A et al (2008) Simultaneous determination of lansoprazole and its metabolites 5-hydroxy lansoprazole and lansoprazole sulphone in human plasma by LC-MS/MS: application to a pharmacokinetic study in healthy volunteers. J Pharm Biomed Anal 48(4):1181-186. doi:10.1016/j.jpba.2008.08.034 CrossRef
17. Teh LK, Lee WL, Amir J, Salleh MZ, Ismail R et al (2007) Single step PCR for detection of allelic variation of MDR1 gene (P-glycoprotein) among three ethnic groups in Malaysia. J Clin Pharm Ther 32(3):313-19. doi:10.1111/j.1365-2710.2007.00822.x CrossRef
18. US Department of Health and Human Services FaDA (2001) Guidance for Industry, Bioanalytical Method
19. Wu GL, Zhou HL, Shentu JZ, He QJ, Yang B et al (2008) Determination of lansoprazole in human plasma by rapid resolution liquid chromatography-electrospray tandem mass spectrometry: application to a bioequivalence study on Chinese volunteers. J Pharm Biomed Anal 48(5):1485-489. doi:10.1016/j.jpba.2008.09.046 CrossRef
20. Xu HR, Chen WL, Li XN, Chu NN et al (2010) The effect of CYP2C19 activity on pharmacokinetics of lansoprazole and its active metabolites in healthy subjects. Pharm Biol 48(8):947-52. doi:10.3109/13880200903300220 CrossRef
21. Zalloum I, Hakooz N, Arafat T (2012) Genetic polymorphism of CYP2C19 in a Jordanian population: influence of allele frequencies of CYP2C19*1 and CYP2C19*2 on the pharmacokinetic profile of lansoprazole. Mol Biol Rep 39(4):4195-200. doi:10.1007/s11033-011-1204-5 CrossRef
22. Zhang D, Wang X, Yang M, Wang G, Liu H et al (2011) Effects of CYP2C19 polymorphism on the pharmacokinetics of lansoprazole and its main metabolites in healthy Chinese subjects. Xenobiotica Fate Foreign Compd Biol Syst 41(6):511-17. doi:10.3109/00498254.2011.559556 CrossRef
23. Zhang D, Yang M, Liu M, Zhang Y, Wang X, Xiao X, Liu H et al (2012) Pharmacokinetics of lansoprazole and its main metabolites after single intravenous doses in healthy Chinese subjects. Xenobiotica Fate Foreign Compd Biol Syst 42(11):1156-162. doi:10.3109/00498254.2012.687119 CrossRef - 作者单位：Chang-Yin Li (1)
Jun Zhang (1)
Ji-Hong Chu (1)
Mei-Juan Xu (1)
Wen-Zheng Ju (1)
Fang Liu (1)
Jian-Dong Zou (1)
1. Department of Clinical Pharmacology, Affiliated Hospital of Nanjing University of Traditional Chinese Medicine, No. 155 Hanzhong Road, 210029, Nanjing, China - ISSN：2107-0180
文摘
Considering that the genotypes of CYP2C19 and MDR1 C3435T are two major factors attributed to the inter-individual pharmacokinetic variability of lansoprazole (LSZ), the aim of the study was to simultaneously elucidate the effects of CYP2C19 and MDR1 C3435T polymorphisms on the pharmacokinetics difference of LSZ and its metabolites 5-hydroxy lansoprazole (HLSZ) and lansoprazole sulphone (LSZS) following oral administration of LSZ tablets in healthy Chinese subjects. Plasma concentration of LSZ, HLSZ and LSZS were quantified by a sensitive and specific LC–MS/MS method, while the genotypes of CYP2C19 and MDR1 C3435T for each subject were identified by a direct sequencing method. Statistical analysis was performed in the pharmacokinetic parameters including C max, t 1/2, T max, MRT0–?/sub>, AUC0- and AUC0–?/sub> among different genotype groups of CYP2C19 and MDR1 C3435T. Compared to the CYP2C19 EMs, the CYP2C19 PM group showed slower elimination and better oral bioavailability of LSZ, much higher plasma concentrations of LSZS and lower concentrations of HLSZ with statistically significance. Despite a tendency of more favorable absorption and rapid elimination of LSZ in wild genotype, no significant pharmacokinetics difference was observed between the wild genotype of MDR1 C3435T and its mutant types. In conclusion, the pharmacokinetics difference of LSZ in Chinese subjects depends much more on the CYP2C19 polymorphism than on the polymorphism of MDR1 C3435T.